



THE WHITE HOUSE
WASHINGTON

COVID-19 Press Briefing

July 22, 2021



Daily Change in COVID-19 Cases, US

January 22, 2020 – July 20, 2021

TOTAL Cases Reported Since 1/22/20

34,030,494

NEW Cases Reported to CDC on 7/20/21

46,318

Change in 7-Day Case Average


+52.5%

Current 7-Day Case Average (7/14/21 - 7/20/21)

37,674

Prior 7-Day Case Average (7/7/21 - 7/13/21)

24,710



New Admissions of Patients with Confirmed COVID-19, US

August 1, 2020 – July 19, 2021

Patients Currently Hospitalized with COVID on 7/19/21

23,351

New Admissions on 7/19/21

3,853

Peak in New Admissions (1/5/21)

17,963

Change in 7-Day Average of New Admissions


+32.2%

Current 7-Day Average of New Admissions (7/13/21 - 7/19/21)

3,521

Prior 7-Day Average of New Admissions (7/6/21 - 7/12/21)

2,663



Daily Change in COVID-19 Deaths, US

January 22, 2020 – July 20, 2021

TOTAL Deaths Reported Since 1/22/2020

607,289

NEW Deaths Reported to CDC on 7/20/21

298

Change in 7-Day Death Average

+19.3%

Current 7-Day Death Average (7/14/21 - 7/20/21)


237

Prior 7-Day Death Average (7/7/21 - 7/13/21)

199

Forecasted Total Deaths by 8/14/21

615,000 to 625,000



Infection After Vaccination: Background

- **Detection of SARS-CoV-2 ≥ 14 days after completion of all recommended doses of FDA-authorized COVID-19 vaccine**
- **Infections after vaccination are expected. No vaccine is 100% effective.**
- **However, even if a vaccine does not completely protect against infection, it usually protects against serious disease**



Typical Viral Vaccines: Classical Outcomes

	Virus		
	Replication	Dissemination	Clearance
Success			
No illness	0	0	Y
No illness	+	0	Y
Mild illness	++	+	Y
Failure			
Frank disease	++++	++++	Y



Pfizer/BioNTech Vaccine



Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine

FP Polack et al. for the
C4591001 Clinical Trial Group

Moderna Vaccine



Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

LR Baden et al. for the
COVE Study Group

Efficacy vs. symptomatic COVID-19:

95%

94.1%



Johnson & Johnson (Janssen) Vaccine



Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against COVID-19

J Sadoff et al. for the ENSEMBLE Study Group

- **66% efficacy overall vs. moderate-to-severe COVID-19**
 - 72% in United States
 - 68% in Brazil
 - 64% in South Africa
- **85% efficacy vs. severe disease across all regions studied**





Effectiveness of COVID-19 Vaccines Against Hospital Admission with the Delta (B.1.617.2) Variant

J Stowe, JL Bernal et al.

- **>14,000 symptomatic COVID-19 cases with Delta variant in England, April-June 2021**
- **Vaccine effectiveness vs. hospitalization with Delta variant (2 doses)**
 - Pfizer-BioNTech – 96%
 - Oxford-AstraZeneca – 92%



THE WHITE HOUSE
WASHINGTON

WH.GOV